MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

Search

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

1.65 10.74

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.47

Max

1.67

Belangrijke statistieken

By Trading Economics

Inkomsten

5.6M

-4.7M

Verkoop

6.1M

6.3M

Winstmarge

-74.681

Werknemers

23

EBITDA

7.3M

-5.1M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+215.54% upside

Dividenden

By Dow Jones

Volgende Winsten

10 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

73M

112M

Vorige openingsprijs

-9.09

Vorige sluitingsprijs

1.65

Nieuwssentiment

By Acuity

50%

50%

141 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 okt 2025, 20:00 UTC

Acquisities, Fusies, Overnames

Infratil Agrees to NZ$437.7 Million Deal to Raise Contact Energy Stake

19 okt 2025, 23:44 UTC

Marktinformatie

Gold Edges Lower Amid Signs of U.S.-China Trade Tensions Easing -- Market Talk

19 okt 2025, 23:37 UTC

Marktinformatie

New Zealand's Core CPI Keeps Rate Cut Hopes Alive -- Market Talk

19 okt 2025, 23:36 UTC

Marktinformatie

Nikkei May Rise, Tracking Wall Street Gains -- Market Talk

19 okt 2025, 23:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

19 okt 2025, 23:09 UTC

Marktinformatie

Could Rio Tinto, BHP Ally to Defend Iron-Ore Pricing Power? -- Market Talk

19 okt 2025, 22:41 UTC

Acquisities, Fusies, Overnames

Luxury Fashion House Kering Confirms Beauty Deal With L'Oréal -- Barrons.com

19 okt 2025, 22:30 UTC

Winsten

Stock Futures Rise Ahead of Major Week of Earnings -- Barrons.com

19 okt 2025, 22:18 UTC

Marktinformatie

Gold at $5,000 on Cards as Investors Get Comfortable -- Market Talk

19 okt 2025, 21:50 UTC

Marktinformatie

Infratil's Contact Stake Buy May Require Bigger Asset Sales -- Market Talk

19 okt 2025, 21:15 UTC

Marktinformatie

Investors Need to Change Narrative Toward Scales -- Market Talk

19 okt 2025, 19:34 UTC

Acquisities, Fusies, Overnames

Infratil's Contact Shareholding to Rise to 14.3% When Deal Completes

19 okt 2025, 19:34 UTC

Acquisities, Fusies, Overnames

Infratil to Issue New Shares Worth NZ$218.8 Million to TECT at NZ$12.43 Each

19 okt 2025, 19:33 UTC

Acquisities, Fusies, Overnames

Infratil Part-Funding Purchase of Contact Energy Stake With NZ$218.8 Million of Existing Debt

19 okt 2025, 19:32 UTC

Acquisities, Fusies, Overnames

Infratil Acquiring Additional Contact Energy Stake for NZ$8.95/Share

19 okt 2025, 19:32 UTC

Acquisities, Fusies, Overnames

Infratil Acquiring Contact Energy Stake for NZ$437.7 Million

19 okt 2025, 19:31 UTC

Acquisities, Fusies, Overnames

Infratil Acquiring TECT Holdings's Shareholding in Contact Energy

19 okt 2025, 19:31 UTC

Acquisities, Fusies, Overnames

Infratil to Acquire Additional 4.92% Stake in Contact Energy

19 okt 2025, 16:29 UTC

Winsten

Elon Musk Pay Drama Heats Up Ahead of Tesla Earnings -- Barrons.com

19 okt 2025, 11:14 UTC

Winsten

Zijin Mining 3Q Oper Income CNY86.49B; up 8.1% on Year>2899.HK

19 okt 2025, 11:14 UTC

Winsten

Zijin Mining: Higher Sales of Gold, Copper Supported Results >2899.HK

19 okt 2025, 11:14 UTC

Winsten

Zijin Mining 3Q Net CNY14.57B; up 57.1% on Year>2899.HK

18 okt 2025, 13:30 UTC

Acquisities, Fusies, Overnames

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 okt 2025, 13:30 UTC

Acquisities, Fusies, Overnames

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 okt 2025, 13:30 UTC

Acquisities, Fusies, Overnames

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 okt 2025, 13:30 UTC

Acquisities, Fusies, Overnames

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 okt 2025, 08:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

17 okt 2025, 23:25 UTC

Acquisities, Fusies, Overnames

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 okt 2025, 22:15 UTC

Marktinformatie

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 okt 2025, 21:15 UTC

Marktinformatie

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

215.54% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.67 USD  215.54%

Hoogste 7 USD

Laagste 1.5 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

8

Buy

0

Hold

0

Sell

Technische score

By Trading Central

0.275 / 0.33Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

141 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat